Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CME Group Inc. SEC filings document the financial results, governance matters and market-infrastructure disclosures of a derivatives exchange and clearing operator. Form 8-K reports cover quarterly and annual results, GAAP and non-GAAP measures, pricing disclosures, material agreements and other events tied to the company’s trading, clearing, benchmark and market data activities.
The filings also describe clearing-house liquidity arrangements, including amendments to a multi-currency secured credit facility used for temporary liquidity needs related to clearing obligations and collateral mechanics. Proxy materials cover executive compensation, pay-versus-performance data, shareholder voting matters and governance. Other event reports have addressed officer transition disclosures and legal matters involving CME Group and the Board of Trade of the City of Chicago.
Morgan Stanley Smith Barney LLC Executive Financial Services reported proposed sales under a Form 144 of several equity award lots, including 2,947 Performance Shares dated 03/15/2024 and multiple Restricted Stock lots dated 03/16/2024, 09/15/2024, and 09/15/2025 with counts of 498, 180, 475, 525, and 535 respectively.
CME Group Inc. director Elizabeth A. Cook reported an indirect open-market sale of 1,000 shares of Class A common stock held by a trust on March 6, 2026, at $320 per share. After this transaction, the trust’s indirect holdings totaled 17,771 CME Group shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting a proposed sale of 1,000 common shares tied to CME with an aggregate value listed as $320,000.00 and an execution date of 03/06/2026.
The filing also lists restricted stock lots of 748 shares with grant date 06/25/2024 and 252 shares with grant date 06/26/2023.
CME Group Inc: The Vanguard Group filed Amendment No. 9 to a Schedule 13G/A reporting 36,248,559 shares beneficially owned, representing 10.10% of common stock. The filing states shared voting power 3,697,661 and shared dispositive power 36,248,559. It notes an internal realignment effective 01/12/2026 that changed portfolio management and proxy voting roles within The Vanguard Group, Inc.
CME Group Inc. files its annual report outlining a broad derivatives, clearing, cash markets and data business built around global benchmark futures and options, cash U.S. Treasuries, FX and market data services. The company emphasizes deep liquidity, risk management and capital efficiency for a diverse institutional customer base.
In 2025, futures and options average daily volume reached 28.1 million contracts, with strong growth in interest rates, agricultural, energy and metals products and micro contracts. Cash markets via BrokerTec and EBS generated $283.7 million in clearing and transaction fees. CME estimates average daily margin savings of about $72 billion from portfolio offsets and cross‑margining.
CME highlights strategic initiatives in product expansion, global distribution, OTC alternatives, crypto, environmental products and a major multi‑year migration of core systems to Google Cloud. It is launching a new securities clearing subsidiary to support upcoming SEC U.S. Treasury and repo clearing mandates and continues to grow licensing and benchmark businesses such as CME Term SOFR. The report also details extensive regulatory oversight, key risk factors and human capital metrics, including roughly 3,875 employees worldwide and strong engagement scores.
CME Group Inc. director Bryan T. Durkin reported an open-market sale of Class A common stock. On February 23, 2026, he sold 4,200 shares at a weighted average price of $309.65 per share, within a price range of $309.25 to $310.07. After this transaction, he directly holds 43,007 shares of CME Group Class A common stock.
CME Group submitted a Form 144 reporting a proposed sale of common shares. The notice lists a broker, Morgan Stanley Smith Barney LLC, and an intended sale date of 02/23/2026. The filing itemizes equity awards: 218 performance stock units (03/15/2021), 3,285 performance stock units (03/15/2021) and 697 restricted shares (09/15/2019).
CME Group Inc. director Martin J. Gepsman reported an open-market sale of Class A common stock. He sold 300 shares at a price of $305.90 per share. After this sale, he directly owns 24,999 shares of CME Group Class A common stock.
CME Group Inc. director Dennis Suskind reported selling 748 shares of Class A common stock on February 6, 2026 at a price of $300 per share. After this transaction, he beneficially owned 2,699 shares of CME Group common stock in direct ownership.